Syncona (SYNC) has announced a major clinical milestone at portfolio company Beacon Therapeutics after its gene therapy, laru-zova, delivered a positive topline result in the pivotal Phase II/III VISTA trial for X-linked retinitis pigmentosa (XLRP).
The trial met its FDA-endorsed primary endpoint, with laru-zova demonstrating a statistically significant improvement in low luminance visual acuity compared with the untreated control group after 12 months.
XLRP is a severe inherited retinal disease that causes progressive sight loss and can ultimately lead to blindness. There are estimated to be more than 20,000 patients in the US and Europe and there are currently no approved treatments.
In the VISTA study, 31.0% of patients receiving the high dose of laru-zova achieved an improvement of at least 15 letters on an eye chart in low luminance conditions, compared with no responders in the untreated control group. The responder rate for the low-dose group was 24.1%.
Beacon said laru-zova also demonstrated a favourable safety and tolerability profile consistent with previous studies.
The result means VISTA is the first pivotal trial in XLRP to achieve an FDA-endorsed primary endpoint and represents what Syncona describes as a key value inflection point for Beacon.
Beacon now plans to begin discussions with regulators globally and intends to initiate a rolling Biologics License Application submission later this year. The full clinical dataset is due to be presented at the American Academy of Ophthalmology Annual Meeting on 10 October.
Beacon was valued at £183.4m in Syncona’s portfolio at 30 June 2026, including equity and deferred consideration attributable to Syncona. Syncona owns 38.4% of the business.
Syncona said the positive result materially de-risks Beacon’s lead programme and has the potential to support significant future NAV growth, either through further financing, a potential IPO or an eventual realisation.
Syncona chief executive Chris Hollowood said the result provided “a powerful validation” of the group’s decision to acquire the programme through AGTC and support its development through late-stage clinical trials.
He added that the data underlined Syncona’s belief that attractive value can be created through investing in later-stage life science opportunities as well as through company formation.
Matthew Read, senior analyst at QuotedData, said: “This is a welcome result for Syncona. Beacon is one of its largest holdings and the fact that laru-zova has met its pivotal trial’s FDA-endorsed primary endpoint materially reduces the risk around the programme and moves it a significant step closer to potential approval. With Beacon valued at £183.4m at the end of June and Syncona owning 38.4%, there is clearly scope for this success to translate into a meaningful NAV uplift over time.
“There is still regulatory work to do, and we will want to see the full dataset in October, but, after a difficult few years, positive clinical delivery from one of its key assets not only provides a useful validation of Syncona’s strategy but also illustrates the logic underpinning shareholders decision to reject proposals for a managed wind down last year.”
